Promising antidiabetic potential of fucoxanthin isolated from the edible brown algae Eisenia bicyclis and Undaria pinnatifida

Fisheries Science

Volumn 78, Issue 6, 2012, Pages 1321-1329

  Jung, Hyun Ah ^a   Islam, Md Nurul ^b   Lee, Chan Mee ^b   Jeong, Hyong Oh ^c   Chung, Hae Young ^c   Woo, Hee Chul ^b   Choi, Jae Sue ^b  

^a Chonbuk National University   (South Korea)

^b Pukyong National University   (South Korea)

^c Pusan National University   (South Korea)

Author keywords

Diabetes mellitus; Diabetic complication; Enzyme kinetic; Fucoxanthin; Molecular docking; PTP1B

Indexed keywords

EISENIA BICYCLIS; PHAEOPHYCEAE; RATTUS; UNDARIA; UNDARIA PINNATIFIDA;

EID: 84869140355     PISSN: 09199268     EISSN: 14442906     Source Type: Journal    
DOI: 10.1007/s12562-012-0552-y     Document Type: Article

References (38)

1. American Diabetes Association (2005) Diagnosis and classification of diabetes mellitus. Diabetes Care 28: S37-S42.
2. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
3. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ (2001) Association of depression and diabetes complications: a meta-analysis. Psychosom Med 63: 619-630.
4. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14.
5. El-Kabbani O, Ruiz F, Darmanin C, Chung RP (2004) Aldose reductase structures: implications for mechanism and inhibition. Cell Mol Life Sci 61: 750-762.
6. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
7. Laakso M (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48: 937-942.
8. Bhandari MR, Anurakkun NJ, Hong G, Kawabata J (2008) α-Glucosidase and α-amylase inhibitory activities of Nepalese medicinal herb Pakhanbhed (Bergenia ciliata, Haw.). Food Chem 106: 247-252.
9. Zhang S, Zhang ZY (2007) PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today 12: 373-381.
10. Barford D, Flint AJ, Tonks NK (1994) Crystal structure of human protein tyrosine phosphatase 1B. Science 263: 1397-1404.
11. Kamerlin SC, Rucker R, Boresch S (2007) A molecular dynamics study of WPD-loop flexibility in PTP1B. Biochem Biophys Res Commun 356: 1011-1016.
12. Wiesmann C, Barr KJ, Kung J, Zhu J, Erlanson DA, Shen W, Fahr BJ, Zhong M, Taylor L, Randall M, McDowell RS, Hansen SK (2004) Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struc Mol Biol 11: 730-737.
13. Matsuno T (2001) Aquatic animal carotenoids. Fish Sci 67: 771-783.
14. Miyashita K, Nishikawa S, Beppu F, Tsukui T, Abe M, Hosokawa M (2011) The allenic carotenoid fucoxanthin, a novel marine nutraceutical from brown seaweeds. J Sci Food Agric 91: 1166-1174.
15. D'Orazio N, Gemello E, Gammone MA, de Girolamo M, Ficoneri C, Riccioni G (2012) Fucoxanthin: a treasure from the sea. Mar Drugs 10: 604-616.
16. Maeda H, Hosokawa M, Sashima T, Miyashita K (2007) Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J Agric Food Chem 55: 7701-7706.
17. Maeda H, Tsukui T, Sashima T, Hosokawa M, Miyashita K (2008) Seaweed carotenoid, fucoxanthin, as a multi-functional nutrient. Asia Pac J Clin Nutr 17: 196-199.
18. Hosokawa M, Miyashita T, Nishikawa S, Emi S, Tsukui T, Beppu F, Okada T, Miyashita K (2010) Fucoxanthin regulates adipocytokine mRNA expression in white adipose tissue of diabetic/obese KK-Ay mice. Arch Biochem Biophys 504: 17-25.
19. Kotake-Nara E, Sugawara T, Nagao A (2005) Antiproliferative effect of neoxanthin and fucoxanthin on cultured cells. Fish Sci 71: 459-461.
20. Hosokawa M, Wanezaki S, Miyauchi K, Kurihara H, Kohno H, Kawabara J, Odashima S, Takahashi K (1999) Apoptosis-inducing effect of fucoxanthin on human leukemia cell line HL-60. Food Sci Technol Res 5: 243-246.
21. Hayman S, Kinoshita JH (1965) Isolation and properties of lens aldose reductase. J Biol Chem 240: 877-882.
22. Nishimura C, Yamaoka T, Mizutani M, Yamashita K, Akera T, Tanimoto T (1991) Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system. Biochim Biophys Acta 1078: 171-178.
23. Vinson JA, Howard TB III (1996) Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. J Nutr Biochem 7: 659-663.
24. Cui L, Na M, Oh H, Bae EY, Jeong DG, Ryu SE, Kim S, Kim BY, Oh WK, Ahn JS (2006) Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett 16: 1426-1429.
25. Li T, Zhang XD, Song YW, Liu JW (2005) A microplate-based screening method for α-glucosidase inhibitors. Chin J Clin Pharmacol Ther 10: 1128-1134.
26. Lineweaver H, Burk D (1934) The determination of enzyme dissociation constants. J Am Chem Soc 56: 658-666.
27. Dixon M (1953) The determination of enzyme inhibitor constants. Biochem J 55: 170-171.
28. Cornish-Bowden A (1974) A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem J 137: 143-144.
29. Peyrou J, Sternberg M (2006) Advanced glycation end products (AGEs): pharmacological inhibition in diabetes. Pathol Biol 54: 405-419.
30. Kaneko M, Bucciarelli M, Hwang YC, Lee L, Yan SF, Schmidt AM, Ramasamy R (2005) Aldose reductase and AGE-RAGE pathway: key players in myocardial ischemic injury. Ann NY Acad Sci 1043: 702-709.
31. de la Fuente JA, Manzanaro S, Martín MJ, de Quesada TG, Reymundo I, Luengo SM, Gago F (2003) Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product. J Med Chem 46: 5208-5221.
32. Tonks NKP (2003) TP1B: from the sidelines to the front lines! FEBS Lett 546: 140-148.
33. Lee S, Wang Q (2007) Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B. Med Res Rev 27: 553-573.
34. Szczepankiewicz BG, Liu G, Hajduk PJ, Abad-Zapatero C, Pei Z, Xin Z, Lubben TH, Trevillyan JM, Stashko MA, Ballaron SJ, Liang H, Huang F, Hutchins CW, Fesik SW, Jirousek MR (2003) Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc 125: 4087-4096.
35. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
36. Hashimoto T, Ozaki Y, Taminato M, Das SK, Mizuno M, Yoshimura K, Maoka T, Kanazawa K (2009) The distribution and accumulation of fucoxanthin and its metabolites after oral administration in mice. Br J Nutr 102: 242-248.
37. Asai A, Sugawara T, Ono H, Nagao A (2004) Biotransformation of fucoxanthinol into amarouciaxanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites. Drug Metab Dispos 32: 205-211.
38. Peng J, Yuan JP, Wu CF, Wang JH (2011) Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar Drugs 9: 1806-1828.